Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of prostacyclin to inhibit activation of platelets during preparation of platelet concentrates

Use of prostacyclin to inhibit activation of platelets during preparation of platelet concentrates Increased utilization of platelet concentrates (PCs) has created the possibility that demand for this blood component may exceed supply. It seems possible that this problem could be minimized if platelets could be isolated from whole blood and stored with full retention of hemostatic effectiveness. We prepared PCs by adding prostacyclin (PGI2) during the isolation procedure and compared these to PCs prepared without addition of PGI2. At concentration 10(‐7) M, PGI2 inhibited activation of platelets during the process of concentration and resuspension by the criteria of minimal thromboxane production and release of beta thromboglobulin (beta‐TG), in contrast to concentrates prepared by standard methods. These differences persisted throughout 3 days of storage at room temperature. Our findings suggest that further studies are indicated to determine whether the quality (hemostatic effectiveness) of concentrated platelets can be improved by pharmacologic means. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Use of prostacyclin to inhibit activation of platelets during preparation of platelet concentrates

Transfusion , Volume 24 (6) – Dec 12, 1984

Loading next page...
 
/lp/wiley/use-of-prostacyclin-to-inhibit-activation-of-platelets-during-vT1rDcQ6nQ

References (25)

Publisher
Wiley
Copyright
Copyright © 1984 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.1984.24685066818.x
Publisher site
See Article on Publisher Site

Abstract

Increased utilization of platelet concentrates (PCs) has created the possibility that demand for this blood component may exceed supply. It seems possible that this problem could be minimized if platelets could be isolated from whole blood and stored with full retention of hemostatic effectiveness. We prepared PCs by adding prostacyclin (PGI2) during the isolation procedure and compared these to PCs prepared without addition of PGI2. At concentration 10(‐7) M, PGI2 inhibited activation of platelets during the process of concentration and resuspension by the criteria of minimal thromboxane production and release of beta thromboglobulin (beta‐TG), in contrast to concentrates prepared by standard methods. These differences persisted throughout 3 days of storage at room temperature. Our findings suggest that further studies are indicated to determine whether the quality (hemostatic effectiveness) of concentrated platelets can be improved by pharmacologic means.

Journal

TransfusionWiley

Published: Dec 12, 1984

There are no references for this article.